- Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
- Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
- Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
- Nuvectis Pharma to Present at the 36th Annual Roth Conference
- Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
- Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
- Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
- Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
- Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.10 |
---|---|
High | 6.99 |
Low | 6.10 |
Bid | 6.50 |
Offer | 10.60 |
Previous close | 6.67 |
Average volume | 94.89k |
---|---|
Shares outstanding | 18.36m |
Free float | 8.51m |
P/E (TTM) | -- |
Market cap | 122.43m USD |
EPS (TTM) | -1.40 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼